This is a summary of the European public assessment report (EPAR) for Pheburane. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Pheburane. For practical information about using Pheburane, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of chronic management of urea-cycle disorders.
Therapeutic Area (MeSH)
N/AATC Code
A16AX03
ATC Item
sodium phenylbutyrate
Pharmacotherapeutic Group
Various alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Sodium phenylbutyrate | N/A | 苯丁酸钠 |
EMA Name
Pheburane
Medicine Name
Pheburane
Aliases
N/ANo risk management plan link.
